Complete Remission of Squamous Cell Carcinoma After Treatment With Panitumumab in a Patient With Cetuximab-Induced Anaphylaxis
Author(s) -
A. Marti,
A. Fauconneau,
N. Ouhabrache,
M. BeylotBarry,
Anne PhamLedard
Publication year - 2015
Publication title -
jama dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.128
H-Index - 166
eISSN - 2168-6084
pISSN - 2168-6068
DOI - 10.1001/jamadermatol.2015.4134
Subject(s) - medicine , cetuximab , panitumumab , anaphylaxis , basal cell , oncology , dermatology , immunology , allergy , cancer , colorectal cancer
observed reaction is also doubtfully drug related, since there were no liver test abnormalities found. The dermatophytid (id) reaction was excluded by the following observations: First, clinical lesions of id reactions are typically intensely pruritic and develop quite distantly from the site of infection.6 In the present case, the patient denied pruritus, and the exacerbation involved the primary lesions without production of any new ones. Second, in id reactions, no fungal forms are recovered from the lesions; in the present case, the patient’s lesions yielded fungal growth. Third, over the course of id reactions, no generalized symptoms (eg, fever), as seen in this patient, are normally observed. Altogether, this report presents an unusual case of a paradoxical reaction resembling, to some extent, the JHR, after treatment of dermatophyte infection with terbinafine.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom